[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336010-105":59,"doc-detail-336010-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","adipocyte-precursor-derived-nrg1-promotes-resistance-to-fgfr-inhibition-in-urothelial-carcinoma","Adipocyte Precursor-Derived NRG1 Promotes Resistance to FGFR Inhibition in Urothelial Carcinoma","","Aberrations in the fibroblast growth factor receptor (FGFR) pathway are common in metastatic urothelial cancer, where pan-FGFR inhibition with erdafitinib often yields only an initial response before rapid, acquired resistance emerges. Adipocyte precursors drive this resistance in a paracrine manner by secreting neuregulin 1 (NRG1), which activates ERBB3/HER3 signaling and renders FGFR-dependent tumor cells less sensitive to erdafitinib. Pertuzumab-mediated blockade of the NRG1/HER3 axis reverses erdafitinib resistance in vitro and extends survival in bladder cancer xenografts. Single-cell RNA sequencing links NRG1 enrichment to inflammatory cancer-associated fibroblasts and highlights a mechanism potentially addressable with existing targeted therapies.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/adipocyte-precursor-derived-nrg1-promotes-resistance-to-fgfr-inhibition-in-urothelial-carcinoma/336010/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/adipocyte-precursor-derived-nrg1-promotes-resistance-to-fgfr-inhibition-in-urothelial-carcinoma/336010.png","ImageObject",300,407,{"name":92,"@type":93},"Anda","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why does erdafitinib resistance develop in metastatic urothelial cancer?","Question",{"text":112,"@type":113},"Although erdafitinib can initially respond in patients with FGFR2/3 alterations, resistance develops rapidly. The study links acquired resistance to paracrine signaling driven by adipocyte precursors via NRG1 and ERBB3/HER3 activation.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What role do adipocyte precursors and NRG1 play in resistance?",{"text":117,"@type":113},"Adipocyte precursors promote resistance to erdafitinib in a paracrine manner. Secreted NRG1 mediates resistance by activating ERBB3/HER3 signaling, and knocking down NRG1 in adipocyte precursors removes the induced resistance.",{"name":119,"@type":110,"acceptedAnswer":120},"How can NRG1/HER3 signaling be targeted to overcome resistance?",{"text":121,"@type":113},"Pharmacologic inhibition of the NRG1/HER3 axis with pertuzumab reverses erdafitinib resistance in tumor cells in vitro. In vivo, pertuzumab plus the relevant context prolongs survival in mice bearing bladder cancer xenografts.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},336010,1790158677,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":4},962075006959,"https://ap-avatar.wpscdn.com/avatar/e0002397efbe92a78e?_k=1776741047341049297","Adipocyte Precursor-Derived NRG1 Promotes Resistance to FGFR Inhibition in Urothelial Carcinoma  \nSana Hosni1, Viola Kilian1, Niklas Kl€umper1,2, Daniela Gabbia3, Katharina Sieckmann4, Dillon Corvino2, Anja Winkler1, Miriam Saponaro1, Karin W€orsd€orfer1, Doris Schmidt1, Oliver Hahn5,6, Ilaria Zanotto3, Marina Bertlich1, Marieta Toma7, Tobias Bald2, Markus Eckstein8, Michael H€olzel2, Matthias Geyer9, Manuel Ritter1, Dagmar Wachten4, Sara De Martin3, and Abdullah Alajati1  \nABSTRACT  \n◥  \nAberrations of the ﬁbroblast growth factor receptor (FGFR) family members are frequently observed in metastatic urothelial cancer (mUC), and blocking the FGF/FGFR signaling axis is used as a targeted therapeutic strategy for treating patients. Erdaﬁtinibis a pan-FGFR inhibitor, which has recently been approved by the FDA for mUC with FGFR2/3 alterations. Although mUC patients show initial response to erdaﬁtinib, acquired resistance rapidly develops. Here, we found that adipocyte precursors promoted resistance to erdaﬁtinib in FGFR-dependent bladder and lung cancer in a paracrine manner. Moreover, neuregulin 1 (NRG1) secreted from adipocyte precursors was a mediator of erdaﬁtinib resistance by activating human epidermal growth factor receptor 3 (ERBB3; also known as HER3) signaling, and knockdown of NRG1 in adipocyte precursors abrogated the conferred paracrine resistance. NRG1 expression was signiﬁcantly downregulated in terminally differentiated adipocytes compared with their progenitors. Pharmacologic inhibition of the NRG1/HER3 axis using pertuzumab reversed erdaﬁtinib resistance in tumor cells in vitro and prolonged survival of mice bearing bladder cancer xenografts in vivo. Remarkably, data from single-cell RNA sequencing revealed that NRG1 was enriched in platelet-derived growth factor receptor-A (PDGFRA) expressing inﬂammatory cancerassociated ﬁbroblasts, which is also expressed on adipocyte precursors. Together, this work reveals a paracrine mechanism of anti-FGFR resistance in bladder cancer, and potentially other cancers, that is amenable to inhibition using available targeted therapies.  \nSigniﬁcance: Acquired resistance to FGFR inhibition can be rapidly promoted by paracrine activation of the NRG1/HER3 axis mediated by adipocyte precursors and can be overcome by the combination of pertuzumab and erdaﬁtinib treatment.  \nSee related commentary by Kolonin and Anastassiou, p. 648  \nIntroduction  \nFor decades, platinum-based combination chemotherapy has been the standard therapy for metastatic urothelial cancer (mUC) . However, this treatment is generally not curative and has a limited impact on patient survival. Although the advent of immunotherapy and  \n1Department of Urology and Pediatric Urology, University Hospital Bonn (UKB), Bonn, Germany. 2Institute of Experimental Oncology, University Hospital Bonn (UKB), Bonn, Germany. 3Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy. 4 Institute of Innate Immunity, Medical Faculty, University of Bonn, Bonn, Germany. 5Clinic of Urology, University Hospital G€ottingen, G€ottingen, Germany. 6Clinic of Urology, University Hospital W€urzburg, W€urzburg, Germany. 7Institute of Pathology, University Hospital Bonn (UKB), Bonn, Germany. 8 Institute of Pathology, University Hospital Erlangen, Erlangen-Nuernberg (FAU), Erlangen, Germany. 9 Institute of Structural Biology, Medical Faculty, University of Bonn, Bonn, Germany.  \nS. Hosni and V. Kilian contributed equally to this article.  \nantibody–drug conjugates has broadened the therapeutic armamentarium for mUC, only a minority of patients respond (1, 2) . The ﬁbroblast growth factor receptor (FGFR) family are receptor tyrosine kinases (RTK), which regulate various cellular functions including cell proliferation, survival, differentiation, and migration. Activation ofthe members of the FGFR family (FGFR1–4) leads to activation of  \nCorresponding Author: Abdullah Alajati, Department of Urology and Pediatric U","cbCailYZWeY3MLNh","https://ap.wps.com/l/cbCailYZWeY3MLNh","pdf",18553158,16,"English","# Abstract\n## Introduction\n## Mechanistic background of FGFR inhibition and resistance","[{\"question\":\"Why does erdafitinib resistance develop in metastatic urothelial cancer?\",\"answer\":\"Although erdafitinib can initially respond in patients with FGFR2/3 alterations, resistance develops rapidly. The study links acquired resistance to paracrine signaling driven by adipocyte precursors via NRG1 and ERBB3/HER3 activation.\"},{\"question\":\"What role do adipocyte precursors and NRG1 play in resistance?\",\"answer\":\"Adipocyte precursors promote resistance to erdafitinib in a paracrine manner. Secreted NRG1 mediates resistance by activating ERBB3/HER3 signaling, and knocking down NRG1 in adipocyte precursors removes the induced resistance.\"},{\"question\":\"How can NRG1/HER3 signaling be targeted to overcome resistance?\",\"answer\":\"Pharmacologic inhibition of the NRG1/HER3 axis with pertuzumab reverses erdafitinib resistance in tumor cells in vitro. In vivo, pertuzumab plus the relevant context prolongs survival in mice bearing bladder cancer xenografts.\"}]","Adipocyte Precursor-Derived NRG1 Promotes Resistance to FGFR Inhibition in Urothelial Carcinoma | PDF",1790013155]